MERCK’S LIPFENDRA® (ENLICITIDE) IS THE FIRST AND ONLY ONCE-DAILY ORAL PCSK9 INHIBITOR APPROVED BY THE U.S. FDA TO REDUCE LDL-C IN ADULTS WITH HYPERCHOLESTEROLEMIA

Reuters · 2d ago

Please log in to view news